Edgen Stock·Sep 19 2025, 23:04戻る
戻る
Johnson & Johnson Regimen Demonstrates Strong Efficacy in Newly Diagnosed Multiple Myeloma
Edgen Stock·Sep 19 2025, 23:04
[1] TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma[2] Johnson & Johnson (JNJ) Immune-Based Regimen Shows Promising Results in Multiple Myeloma Trial - GuruFocus[3] Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients - Benzinga